Heterologous vaccination utilizing viral vector and protein platforms confers complete protection against SFTSV.

MLA

Kim, Jae-Yong, et al. “Heterologous Vaccination Utilizing Viral Vector and Protein Platforms Confers Complete Protection against SFTSV.” Scientific Reports, vol. 13, no. 1, May 2023, p. 8189. EBSCOhost, https://doi.org/10.1038/s41598-023-35328-9.

APA

Kim, J.-Y., Jeon, K., Hong, J. J., Park, S.-I., Cho, H., Park, H.-J., Kwak, H. W., Park, H.-J., Bang, Y.-J., Lee, Y.-S., Bae, S.-H., Kim, S.-H., Hwang, K.-A., Jung, D.-I., Cho, S. H., Seo, S. H., Kim, G., Oh, H., Lee, H.-Y., … Nam, J.-H. (2023). Heterologous vaccination utilizing viral vector and protein platforms confers complete protection against SFTSV. Scientific Reports, 13(1), 8189. https://doi.org/10.1038/s41598-023-35328-9

Chicago

Kim, Jae-Yong, Kyeongseok Jeon, Jung Joo Hong, Sang-In Park, Hyeonggon Cho, Hyo-Jung Park, Hye Won Kwak, et al. 2023. “Heterologous Vaccination Utilizing Viral Vector and Protein Platforms Confers Complete Protection against SFTSV.” Scientific Reports 13 (1): 8189. doi:10.1038/s41598-023-35328-9.